Search Results

You are looking at 131 - 140 of 496 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen

subtypes are a key determinant. Clinical trials have demonstrated that patients with HR+ (ER+ and/or PR+) breast cancer benefit from tamoxifen, those with HR– (ER– and PR–) benefit from adjuvant chemotherapy, and those with HER2+ disease benefit from

Full access

Fei Gao, Nan Li, YongMei Xu, and GuoWang Yang

for patients with operable stage IIIA NSCLC, and platinum-based adjuvant chemotherapy is currently the standard treatment of patients with good ECOG performance status after surgery. 3 , 4 Postoperative chemotherapy (POCT) can improve disease

Full access

Michaela A. Dinan, Lauren E. Wilson, and Shelby D. Reed

Background The introduction of genomic tests such as the Oncotype DX 21-gene recurrence score (RS) assay has allowed the omission of adjuvant chemotherapy for patients with estrogen receptor (ER)–positive, node-negative breast cancer who have a low

Full access

Yvonne H. Sada, Brandon G. Smaglo, Joy C. Tan, Hop S. Tran Cao, Benjamin L. Musher, and Nader N. Massarweh

.7% received only adjuvant chemotherapy, 18.4% received adjuvant chemotherapy and RT, and 13.9% received only adjuvant RT), whereas 12.8% of those treated with preoperative RT received adjuvant therapy (all of whom received only adjuvant chemotherapy). Table 1

Full access

Traci LeMasters, S. Suresh Madhavan, Usha Sambamoorthi, Hannah W. Hazard-Jenkins, Kimberly M. Kelly, and Dustin Long

receipt of neoadjuvant and adjuvant chemotherapy. Neoadjuvant chemotherapy is given to some women to shrink larger tumors and provide an opportunity for BCS after clinical staging but before pathologic staging. Although tumor size was used to determine the

Full access

Stephen B. Gruber and Wendy Kohlmann

nonpolyposis colorectal carcinoma family members . Cancer 1998 ; 83 : 259 – 266 . 48 Elsaleh H Joseph D Grieu F . Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer . Lancet 2000 ; 355

Full access

Lee S. Schwartzberg

groups was extended to the addition of adjuvant chemotherapy to tamoxifen in the follow-up B-20 trial. 4 Conversely to the effect of endocrine therapy, chemotherapy clearly reduced 10-year distant disease–free recurrence rates in the high RS group, with

Full access

Robert J. Morgan Jr

combination of these modalities. Systemic adjuvant chemotherapy in many cancers is administered after surgery based on efficacy shown in randomized clinical trials. Interestingly, studies have shown that, after informed discussion, substantial proportions of

Full access

Colmar Figueroa-Moseley, Pascal Jean-Pierre, Joseph A. Roscoe, Julie L. Ryan, Sadhna Kohli, Oxana G. Palesh, Elizabeth P. Ryan, Jennifer Carroll, and Gary R. Morrow

1998 ; 6 : 46 – 50 . 8. Razavi D Delvaux N Farvacques C . Prevention of adjustment disorders and anticipatory nausea secondary to adjuvant chemotherapy: a double-blind, placebo-controlled study assessing the usefulness of alprazolam . J

Full access

Bruce D. Minsky, Claus Rödel, and Vincenzo Valentini

versus chemoradiation (50.4 Gy plus continuous-infusion 5-FU). In contrast to the trial from Bujko et al, 38 , 39 patients in both arms received postoperative 5-FU/leucovorin adjuvant chemotherapy. The median follow-up was 5.9 years. Comparing short